US study finds some increase in resistant infections during pandemic

An analysis of antimicrobial resistance at more than 270 U.S. hospitals found some increase during the first 20 months of the COVID-19 pandemic compared with the prior 8 months.
The research was conducted by Becton, Dickinson and Company, Merck and Pfizer. It was presented at the European Congress of Clinical Microbiology and Infectious Diseases.
“It is particularly worrying that antibiotic resistance has been rising during the pandemic in both SARS-CoV-2-positive and SARS-CoV-2-negative patients,” Merck’s Karri A. Bauer, PharmD, said in a news release announcing the findings.

An analysis of antimicrobial resistance at more than 270 U.S. hospitals found some increase during the first 20 months of the COVID-19 pandemic compared with the prior 8 months.
The research was conducted by Becton, Dickinson and Company, Merck and Pfizer. It was presented at the European Congress of Clinical Microbiology and Infectious Diseases.
“It is particularly worrying that antibiotic resistance has been rising during the pandemic in both SARS-CoV-2-positive and SARS-CoV-2-negative patients,” Merck’s Karri A. Bauer, PharmD, said in a news release announcing the findings.